Do you consider it safe to continue adalimumab for spondyloarthritis in a patient who develops localized melanoma if the adalimumab has worked well?  

This is a challenging question as there's a lack of data regarding the impact of anti-TNF agents on melanoma progression. While the safety record for TNFi in the context of malignancy is generally positive, melanoma progression remains unpredictable. In the described case of localized melanoma, my p...